Development of a Model Care Pathway for Myasthenia Gravis

Anil babu Payedimarri, Matteo Ratti, Riccardo Rescinito, Alessandra Vasile, Deborah Seys, Hervé Dumas, Kris Vanhaecht and Massimiliano Panella
Additional contact information
Anil babu Payedimarri: Department of Translational Medicine (DIMET), Università del Piemonte Orientale, 28100 Novara, Italy
Matteo Ratti: Department of Translational Medicine (DIMET), Università del Piemonte Orientale, 28100 Novara, Italy
Riccardo Rescinito: Department of Translational Medicine (DIMET), Università del Piemonte Orientale, 28100 Novara, Italy
Alessandra Vasile: Department of Translational Medicine (DIMET), Università del Piemonte Orientale, 28100 Novara, Italy
Deborah Seys: European Pathway Association, 3000 Leuven, Belgium
Hervé Dumas: UCB Pharma, 1630 Bulle, Switzerland
Kris Vanhaecht: European Pathway Association, 3000 Leuven, Belgium
Massimiliano Panella: Department of Translational Medicine (DIMET), Università del Piemonte Orientale, 28100 Novara, Italy

IJERPH, 2021, vol. 18, issue 21, 1-14

Abstract: Myasthenia Gravis (MG) is a chronic, life-lasting condition that requires high coordination among different professionals and disciplines. The diagnosis of MG is often delayed and sometimes misdiagnosed. The goal of the care pathway (CP) is to add value to healthcare reducing unnecessary variations. The quality of the care received by patients affected with MG could benefit from the use of CP. We conducted a study aimed to define an inclusive, comprehensive, and multidisciplinary CP for the diagnosis, treatment, and care of MG. The development of the model CP, key interventions, and process indicators is based on the literature review and 85 international MG experts were involved in their evaluation, expressing a judgment of relevance through the Delphi study. 60 activities are included in the model CP and evaluated by the MG experts were valid and feasible. The 60 activities were then translated into 14 key interventions and 24 process indicators. We believe that the developed model CP will help for MG patients to have a timely diagnosis and high-quality, accessible, and cost-effective treatments and care. We also believe that the development of model CPs for other rare diseases is feasible and could aid in the integration of evidence-based knowledge into clinical practice.

Keywords: myasthenia gravis; critical pathway; care pathway; model pathway; integrated care pathway; clinical pathway; process flow; core activities; quality indicators; key interventions (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/21/11591/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/21/11591/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:21:p:11591-:d:672075

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().